



Tips on Proposal Preparation and how to Find Partners

Sasha Hugentobler, Health NCP Switzerland | Euresearch

Image by: ©wavebreakmedia/Shutterstock.com




7 December 2023

Training "Improve your Chances to Get Horizon Europe Funding" www.healthncp.net

e

3 Main Rules to Write a Strong Proposal





Research Proposal Template





Horizon Europe Programme Standard Application Form (HE RIA, IA)

Application form (Part A) Project proposal – Technical description (Part B)

> Version 5.0 8 September 2022

- Part A is generated by the IT system, based on the information entered by the participants through the submission system in the Funding & Tenders Portal.
- Part B is the narrative part that includes three sections (Excellence, Impact and Implementation) that each correspond to an evaluation criterion.

- RIAs and IAs type of actions: 45 pages
- First stage proposals: 10 pages





Scientific and Technological Excellence

Sasha Hugentobler, Health NCP Switzerland | Euresearch


Image by: ©wavebreakmedia/Shutterstock.com



www.healthncp.net



Application Form – Part B structure



Evaluation Criteria for Excellence (RIA/IA)



Clarity and pertinence of the project's objectives, and the extent to which the proposed work

is ambitious, and goes beyond the state-of-the-art

- Soundness of the proposed methodology, including the underlying concepts, models, assumptions, interdisciplinary approaches
- appropriate consideration of the gender dimension in research and innovation content
- and the quality of open science practices including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.



Section 1: Excellence (2 sub-chapters)

1. Objectives and Ambition (eg. 4 pages)

Objectives (relevant, measurable, verifiable, and achievable) Beyond state-of-the-art R&I maturity Special Attention of IA- Innovation Action

2. Methodology (eg. 15 pages)

Methodology (concepts, models, specific methods). Publications and Patents as Footnote. Links to other national and international R&I activities Integration of SSH Gender dimension Open science practices Research data management (FAIR principle) Proposed project =

within the scope of a

work programme

topic


Key Aspects to check for the Excellence Section

Idea = **ambitious**

and goes beyond

the state of the art

എ



1.1 Objectives and Ambition1.2 Methodology



9

Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Scope

- Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials
- Test new or improved anti-viral therapeutics
- Innovative delivery systems
- Consider critical social factors: sex, gender, age, socioeconomic factors, ethnicity/migration, and disability

- Apply novel approaches (e.g. AI) for rapid and reliable identification of therapeutics. Engage regulatory bodies.

Expected Outcome

- Increased knowledge on viruses with epidemic potential
- Mechanisms of action for the development of broad-spectrum anti-viral therapeutics
- Scientific and clinical communities have access to novel approaches for the development of anti-viral therapies
- Access to experimental broad-spectrum anti-viral candidates for further clinical investigation
- Therapeutic options for clinical deployment in case of an epidemic or pandemic

Type of Action: RIA

Budget: € 7-8 million /project Deadline: 13 Apr 2023 Total funded projects: 7



Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Scope

- Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials
- Test new or improved anti-viral therapeutics
- Innovative delivery systems
- Consider critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability
- Apply novel approaches (e.g. AI) for rapid and reliable identification of therapeutics.

Engagement with regulatory bodies

Objectives of Proposal VIRALSTOP

- Testing and further develop 2 anti-viral therapeutic in the lab of partner x
- First clinical study of the therapeutic in x and y hospitals of xy partners on xy patients
- Development of one new delivery system at uni xy in the lab
- Regulatory and ethical regulations regarding 3 vulnerable patient groups by 2 partners and patient organization z and y
- Development of one new algorithm for machine learning, AI and test its efficacy of detecting new candidates for anti-viral therapeutics (incl. new AI template requirements!!)

DOs



Check that the objectives are quantifiable

Check hat all topic requirements are addressed

Check that all new AI requirements are met

Don't have too many objectives

&

Don't have objectives that are not relevant regarding the topic requirement

Don't omit reference to relevant publications, patents and collaborations





Impact


Image by: ©wavebreakmedia/Shutterstock.com



www.healthncp.net



Application Form – Part B Structure



Evaluation Criteria for Impact (RIA/IA)



Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme, and the likely scale and significance of the contributions due to the project. Suitability and quality of the measures to maximize expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities.



Section 2: Impact (3 sub-chapters)

- 1. Project's pathways towards impact
- 2. Measures to maximise impact Dissemination, exploitation and communication

3. Summary

Section 2.1:Project's pathways towards impact [e.g. 4 pages

HNN3.0 C

Describe the contribution of your project results

(1) outcomes specified in this topic, and

(2) the wider impacts, in the longer term, specified in the respective destinations in the work programme.

Requirements and potential barriers

Scale refers to how widespread the outcomes and impacts are likely to be. Significance refers to the importance, or value, of those benefits.

Proposals must indicate the likely scale and significance of the project's contribution to outcomes and impacts Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Expected Outcome

 Increased knowledge on viruses with epidemic potential

 Mechanisms of action for the development of broadspectrum anti-viral therapeutics

- Scientific and clinical communities have access to novel approaches for the development of anti-viral therapies
- Access to experimental broad-spectrum anti-viral candidates for further clinical investigation

 Therapeutic options for clinical deployment in case of an epidemic or pandemic Outcome of the project VIRALSTOP

Proposal

X numbers of scientific & medical publications by all partners

A new methodology of.... Developed by partners xy

Trainings for medical staff on new therapies in x hospitals in y countries reaching z patients by partners xy

The project will have found at least 2 anti-viral candidates by partners xy

X new therapies tested in the clinical setting



Section 2.2: Measures to maximise impact - Dissemination, exploitation and communication [e.g. 4 pages]

A first version of 'plan for the dissemination and exploitation including communication activities

Target groups

If exploitation is expected primarily in non-associated third countries, justify by explaining how that exploitation is still in the Union's interest.

Strategy for the management of intellectual property and exploitation

Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Outcome of the project

- X numbers of scientific & medical publications by all partners
- A new methodology of.... Developed by partners xy
- Trainings for medical staff on new therapies in x hospitals in y countries reaching z patients by partners xy
- The project will have found at least 2 anti-viral candidates by partners xy
- X new therapies tested in the clinical setting

Target Groups VIRALSTOP

- show how you engage with
 - Scientist and clinicians in country y and x
 - Companies in the medical sector
 - Medical staff in the hospitals y, x, z
 - Regulators in the countries a, b, c
 - Clinical study patient groups of size x in hospitals a and b



2.2 Summary

→ Canvas

Specific needs, expected results, D & E & C measures, target groups, outcomes, impacts

Provide a summary of this section by presenting a canvas with KIP- Key Impact Pathways. The canvas breaks the impact down into its component parts.

2.3 Summary





Provide a summary of this section by presenting in the canvas below the key elements of your project impact pathway and of the measures to maximise its impact.

Specific Needs

A therapeutic against new viruses

Target Groups

The patients in the x hospitals of the consortium Infected citizens Medical Companies

Expected Results

A new broad therapeutic also for vulnerable groups A new compound D & E & C Measures - Exploitation: a new compound - Dissemination: Scientific and medical publications with the methodology for the new compound and therapy

- **Communication**: A campaign to the citizens of the safety and efficacy of the new therapy

Outcomes

The patients of the x hospitals can benefit from the new therapy A major biotech company or pharma exploits the new compound High use of the scientific and medical discovery publications

Impacts

Scientific: new mode of action of a therapeutic candidate. New compounds found. Increased efficacy.
Economic: a % reduction of patients with severe conditions, reduces costs of health system, hospital, work force
Societal: less death, more stable economy. Provide QALY (Quality Adjusted Life Year)



Be as concise and precise as possible

Address impact short term (duration of project) and long term (10 years from now)

Write an excellent CANVAS

- Don't define impact in qualitative terms only

- Don't omit explaining the means of delivery of end results to users

- Don't be vague regarding targeted stakeholders





Quality of the Implementation


Image by: ©wavebreakmedia/Shutterstock.com



www.healthncp.net



Application Form – Part B Structure



Evaluation Criteria for Implementation (RIA/IA)



Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall. Capacity and role of each participant, and extent to which the consortium as a whole brings together the necessary expertise.


Section 3: Implementation (2 sub-chapters)



3.1 Work plan and resources (e.g. 14 pages – including tables)

3.2 Capacity of participants and consortium as a whole (e.g. 3 pages)

Presentation of the overall structure of the work plan



DOs



Differentiate between milestones and devliverables

Explain expertise and resources per partner

Check coherence between GANT and PERT charts

Forget the contingency plan

&

Don't have too many deliverables and milestones

Don't be vague and unspecific describing tasks





How to find partners

Sasha Hugentobler, Health NCP Switzerland | Euresearch

Image by: ©wavebreakmedia/Shutterstock.com




7 December 2023

Training "Improve your Chances to Get Horizon Europe Funding www.healthncp.net

Consortium – How to?






www.euresearch.ch/health


EU Health info days and brokerage events






EU Health info days and brokerage events





Past EU-project participants – CORDIS





34

Past EU-project participants – CORDIS



PeRsOnalized nutriTion for hEalthy livINg	Name and contact details for the coordinator and participants	
Pact Sheet Results in Brief Reporting Project description Image: Imag	Coordinator Image: Constant	Net EU contribution € 1 085 000,00 Other funding € 0,00
Description of the project and its objectives	HORIZON collaboration network ISI	







Sasha Hugentobler



Thank you

Euresearch | www.euresearch.ch

Sasha Hugentobler| sasha.Hugentobler@euresearch.ch

#healthNCPnet



www.healthncp.net

twitter.com/HealthNCPNet

N

www.youtube.com/channelHealthNCPNet

(in) www.linkedin.com/in/health-ncp-net